Gyre Therapeutics Inc. (L9S)
XFRA 
Summary
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago.
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.01 per share a year ago.
Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates
Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.02 per share a year ago.
Gyre Therapeutics Inc. (L9S) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Gyre Therapeutics Inc. ever had a stock split?
Gyre Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ping Zhang CEO | XFRA Exchange | 403783103 CUSIP |
| US Country | 625 Employees | 12 Jan 2023 Last Dividend | 31 Oct 2023 Last Split | - IPO Date |
Overview
Gyre Therapeutics, Inc., established in 2002 and based in San Diego, California, is a pioneering pharmaceutical company dedicated to the advancement and commercialization of novel small-molecule drugs. These drugs are specifically designed to offer potent anti-inflammatory and anti-fibrotic treatments for organ fibrosis, addressing a significant unmet medical need in various fibrotic diseases. Operating as a subsidiary of GNI USA, Inc., Gyre Therapeutics leverages cutting-edge science to develop therapies that aim to improve the lives of patients battling fibrosis-related conditions.
Products and Services
- ETUARY (Pirfenidone)
An anti-fibrotic drug that represents a significant advancement in the treatment of idiopathic pulmonary fibrosis, ETUARY (Pirfenidone) is currently approved for clinical use. Beyond its established applications, it is under phase 3 studies for multiple conditions including dermatomyositis, systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease, showcasing its potential versatility and far-reaching impact in fibrotic disease treatment.
- F351 (Hydronidone)
As a structural derivative of ETUARY (Pirfenidone), F351 (Hydronidone) is under Phase 3 studies for treating chronic hepatitis B liver fibrosis, demonstrating Gyre Therapeutics’ focus on expanding its portfolio to address liver fibrosis. Additionally, this candidate is under Phase 1 studies for liver fibrosis associated with nonalcoholic steatohepatitis, further highlighting the company’s commitment to combating liver diseases.
- F573
Currently under Phase 2 studies, F573 is aimed at the treatment of acute/acute-on-chronic liver failure, indicating Gyre Therapeutics' dedication to addressing severe liver conditions with cutting-edge therapeutic options.
- F528
At the preclinical stage, F528 is being developed for the treatment of chronic obstructive pulmonary disease (COPD). This development underscores the company’s efforts to tackle respiratory diseases with significant unmet medical needs through innovative therapeutic approaches.
- F230
Also at the preclinical stage, F230 targets the treatment of pulmonary arterial hypertension, a serious condition that can lead to heart failure. Gyre Therapeutics' work on F230 exemplifies its ongoing quest to address a wide range of fibrosis-related diseases by harnessing the potential of its drug development pipeline.
